Larvol Delta - Latebreaking-headtohead-results-reinforce-potential-of-zasocitinib-as-a-nextgeneration-TYK2-inhibitor

zasocitinib (TAK-279) - Takeda

Sotyktu (deucravacitinib) - BMS

https://www.takeda.com/newsroom/news-releases/2026/zasocitinib-superior-efficacy/

Sep 30, 2026

SHARE THIS

Print
Email
More sharing

Reddit

StumbleUpon

Delicious

Next